bristol-myers squibb - Search News

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

Barron's on MSN · 2d

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.

Reuters on MSN · 2d

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.

The Wall Street Journal on MSN · 2d

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.

Fierce Pharma3d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

2d

Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

1d

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

4d

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...

1don MSN

Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best medical stocks to buy according to analysts. Bristol-Myers ...

1d

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

2d

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

2d

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

1don MSN

Bristol-Myers Squibb shares snapped six-session losing streak

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

BioPharma Dive5d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results